medigraphic.com
ISSN 1561-302X (Print)

2015, Number 2

<< Back Next >>

Rev cubana med 2015; 54 (2)

Use of anticoagulation in non-rheumatic atrial fibrillation for stroke prevention

Aguilar LG, Valdés ÁK, Senra ALA

Language: Spanish
References: 37
Page: 129-138
PDF size: 127.06 Kb.


ABSTRACT

Introduction: atrial fibrillation is the most common sustained cardiac arrhythmia. It is associated with increased morbidity and mortality from stroke and other thromboembolic disorders. A antithrombotic treatment is indicated for prophylactic use, as assessed by risk scores (CHA2DS2-VASc).
Objective: determine the frequency of anticoagulation use in non-rheumatic atrial fibrillation prophylaxis of thromboembolic disorders.
Methods: a retrospective observational study was conducted in patients with atrial fibrillation treated at Hermanos Ameijeiras Hospital applying the risk scale for thromboembolism CHA2DS2-VASc. Descriptive statistics tests were applied.
Results: out of 89 patients with atrial fibrillation, the mean age was 77.1 ± 9.5 years, there was a predominance of males (56.2 %). The risk factor most frequently associated with atrial fibrillation was hypertension in 71.9 % of cases. In applying the risk scale, 88 patients were classified as high risk, 69.3 % of them received no treatment, 15.7 % had single antiplatelet therapy, 1.1 % had dual antiplatelet therapy, and only 13.6 % had anticoagulation. No patients with atrial fibrillation at high risk for thromboembolic disorders had a higher score of 3 and, therefore, there was no contraindication for the use of anticoagulants, according to the bleeding risk scale HAS-BLED.
Conclusion: it is insufficient the use of oral anticoagulation in patients admitted to our service with a diagnosis of atrial fibrillation and high risk of stroke.


REFERENCES

  1. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.

  2. Murphy NF, Simpson CR, Jhund PS. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606-12.

  3. Morillas P, Pallarés V, Llisterri JL, Sanchis C, Sánchez T, Fácila L. Prevalencia de fibrilación auricular y uso de fármacos antitrombóticos en el paciente hipertenso ≥ 65 años. El registro FAPRES. Rev Esp Cardiol. 2010;63:943-50.

  4. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYN. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010;123:638-45.

  5. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967-75.

  6. Hughes M, Lip GY, Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99:295-304.

  7. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546-54.

  8. Darkow T, Vanderplas AM, Lew KH. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005;21:1583-94.

  9. Lip GYH, Tse HF, Lane DA. Atrial Fibrillation. Lancet. 2012;379:648-61.

  10. Nieuwlaat R, Capucci A, Lip GY. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018-26.

  11. Glazer NL, Dublin S, Smith NL. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007;167:246-52.

  12. Vázquez E, Martín A, Pousibet H, Lozano C, Guzmán M, Tarabini A, et al. Utilización del tratamiento anticoagulante en los pacientes con fibrilación auricular no reumática. Rev Esp Cardiol. 2000;53:200-4.

  13. Hughes M, Lip GY, for the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100:599-607.

  14. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fi brillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010;104:1099-105.

  15. Lip GYH, Andreotti F, Fauchier L. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723-46.

  16. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.

  17. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173-80.

  18. Barrios V, Calderón A, Escobar C, De la Figuera M. Pacientes con fibrilación auricular asistidos en consultas de atención primaria. Estudio Val-FAAP. Rev Esp Cardiol. 2012;65:47–53.

  19. Padjen V, Jovanovic DR, Leys D, Beslac-Bumbasirevic L. Predicting the outcomes of acute ischaemic stroke in atrial fibrillation: the role of baseline CHADS2, CHA2DS2-VASc and HAS-BLED score values. Acta Cardiol. 2013 Dec;68(6):590-6.

  20. Komatsu T, Sato Y, Ozawa M, Kunugita F, Yoshizawa R, Morino Y, et al. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy. Int Heart J. 2014;55(2):119-25. Epub 2014 Mar 14.

  21. Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H. J-RHYTHM Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED Scores in Japanese Patients With Nonvalvular Atrial Fibrillation. Circ J. 2014 Jun 25;78(7):1593-9. Epub 2014 Apr 22.

  22. Depret-BixioL P, Emery Cotte F, Marie P. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation in General Practice) Database. Clin Res Cardiol. DOI 10.1007/s00392-014-0726-y

  23. Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R. Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes. Estudio AFABE. Rev Esp Cardiol. 2013;66(7):545–52.

  24. García-Acuña JM, González-Juanatey JR, Alegría-Ezquerra E, González-Maqueda I, Listerri JL. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2002;55:943-52.

  25. Rodríguez-Mañero M, Bertomeu-González V, Cordero A, Moreno-Arribas J, Mazón P, Fácila L. Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years. Cardiotens 2009. Rev Port Cardiol. 2013;32:103-9.

  26. Kannel WB. Sixty years of preventive cardiology: a Framingham perspective. Clin Cardiol. Jun. 2011;34(6):342-3. doi: 10.1002/clc.20923.

  27. Meinertz T, Kirch W, Rosin L, Pittrow D. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100:897-905.

  28. Jover E, Roldan V, Gallego P, Hernández-Romero D, Valdés M, Vicente V, et al. Valor predictivo de la escala CHA2DS2-VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. Rev Esp Cardiol. 2012;65:627-33.

  29. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27:1947-3.

  30. Uz O, Atalay M, Doğan M, Isilak Z, Yalcin M, Uzun M, et al. The CHA2DS2-VASc score as a predictor of left atrial thrombus in patients with non-valvular atrial fibrillation. Medical Principles and Practice. 2014;23(3):14-23.

  31. Lip GY, Frison L, Halperin JL. Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731-8.

  32. Roldan V, Marín F, Fernández H, Manzano-Fernández, Gallego P, Valdés M. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real world” anticoagulated atrial fibrillation population. Chest. 2013;143:179-84.

  33. Gallego P, Roldan V, Torregrosa JM, Gálvez J, Valdés M, Vicente V. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrythm Electrophysiol. 2012;5:312-8.

  34. Riesgo A, Sant E, Benito L, Hoyo J, Miró O, Mont L. Diferencias de género en el manejo de los pacientes con fibrilación auricular: análisis de base poblacional en un área básica de salud. Rev Esp Cardiol. 2011;64:233-6.

  35. Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-word patients with atrial fibrillation: the Euro Heart Survey. Am J Med. 2014 May 13. pii: S0002-9343(14)00387-8. doi: 10.1016/j.amjmed.2014.05.003. Epub ahead of print, 2010;27:39-50.

  36. Mazón P, Cordero A, González-Juanatey JR, Galve E, Lekouna I, Facila L. Impacto de la hipertensión arterial en las cardiopatías en España: evolución en la última de cada. Rev Esp Cardiol. 2010;63(Supl 3):53 (A427).

  37. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008:1-11.




2020     |     www.medigraphic.com